Cardiac biomarkers market seen reaching $42.21 billion by 2030

The cardiac biomarkers market is projected to grow from $21.19 billion in 2025 to $42.21 billion by 2030, driven by rising cardiovascular disease rates, faster diagnostics and wider use of point-of-care testing. North America held the largest market share in 2025, according to The Business Research Company’s latest report.

Why it matters: - Cardiac biomarkers are central to faster diagnosis of heart injury and stress, which can improve treatment decisions and patient outcomes. - Rising demand for rapid and preventive cardiac testing is expanding a market tied directly to cardiovascular disease burden and healthcare spending.

What happened: - The Business Research Company published its Cardiac Biomarkers Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on July 30, 2026. - The report says the cardiac biomarkers market rose from $21.19 billion in 2025 to a forecast $24.22 billion in 2026. - The same report projects the market will reach $42.21 billion by 2030. - A free sample of the report is available here. - The full report is available here.

The details: - The report puts 2025-2026 growth at a 14.3% compound annual growth rate. - The forecast period through 2030 carries a 14.9% CAGR. - The report links growth to rising cardiovascular disease prevalence, expansion of emergency cardiac care services, broader acceptance of laboratory diagnostics and stronger use of biomarker-based testing. - Advancements in immunoassay technology also support the market. - Future growth drivers include rapid cardiac diagnostics, decentralized testing, preventive cardiology screenings, investment in diagnostic platforms and digital health analytics. - Emerging trends include high-sensitivity troponin assays, point-of-care cardiac testing, fast diagnostic kits, multiplex biomarker panels and earlier detection of cardiac risk factors. - Cardiac biomarkers are substances released into the bloodstream when the heart is injured or under stress. - These biomarkers help clinicians identify cardiovascular conditions and choose treatment plans. - North America held the largest regional share in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - Higher healthcare expenditures are helping fund diagnostic tools that support earlier detection and more targeted care. - The market is shifting toward faster, more distributed testing, which suggests hospitals and clinics are prioritizing speed and access over centralized lab workflows. - The report’s emphasis on high-sensitivity assays and multiplex panels points to a market moving toward more detailed and earlier risk detection. - UK healthcare spending rose 5.6% in nominal terms from 2022 to 2023, after a 0.9% increase in 2022, according to a May 2024 Office for National Statistics report.

What's next: - The Business Research Company says the market’s next phase will likely be shaped by broader use of decentralized testing models and digital diagnostics. - More investment in rapid-testing platforms and preventive screening could push cardiac biomarkers deeper into routine care. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated graphics and tables.

The bottom line: - Cardiac biomarker testing is moving from a specialized diagnostic tool toward a larger, faster and more data-driven market.